New data provide insight into anti-CGRP use
From: The Pharma Letter New data provide insight into anti-CGRP use A survey from industry analyst Spherix Global Insights suggests that more people may be using anti-calcitonin…(read more)
Unimpeded by Allergan’s Botox Dominance, Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
Teva’s Ajovy may be most at risk by the future availability of orally dosed anti-CGRP therapies, including Biohaven’s rimegepant and Allergan’s atogepant, while Allergan’s Botox will remain insulated from anti-CGRP class pressure, according to the inaugural Spherix Global Insights audit of the US migraine prevention market EXTON, Pa., September 11, 2019 ― Contributing physicians appear […]
With Continued Uptake in the US, Both EMD Serono’s Mavenclad and Novartis’ Mayzent Must Successfully Woo Multiple Sclerosis Patient Candidates from Genentech’s Ocrevus (and Each Other) to Succeed, According to the 15th Wave of the Quarterly Spherix Global Insights Report
Genentech’s best strategy for escaping the competitive pressure from these new oral market entrants, as well as future monoclonal antibodies like Novartis’ ofatumumab and TG Therapeutics’ ublituximab, will be the continued execution on establishing Ocrevus as a preferred first-line option in the relapsing-remitting multiple sclerosis treatment algorithm EXTON, Pa., September 9, 2019 ― Four months […]
Novartis’ Gilenya, Sanofi’s Aubagio, Biogen’s Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement
Although overall switch share for Roche’s Ocrevus is hampered by low treatment and switch rates for primary progressive multiple sclerosis, European neurologists vastly underestimate the dominance of the brand among such treated patients as revealed in the new audit by Spherix Global Insights EXTON, Pa., August 13, 2019 ― According to Spherix’s new audit included […]
Impact of US Physicians’ Perceptions of the Distinct Pharmacological and Clinical Characteristics of the Novel Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Self-Reported Chronic Migraine Prevention Brand Share
Authors: Virginia R. Schobel, MSc; Jennifer Robinson MSc BACKGROUND: Therapeutic choice for the prevention of episodic and chronic migraine increased with the recent approvals of anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies, specifically erenumab-aooe, fremanezumab-vfrm, and galcanezumab-gnlm. We aim to assess how, with limited time on the market, physicians’ perceptions of these agents’ pharmacological […]
Early Prescribing Patterns of the Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies Are Dominated by Adjunctive Use for Episodic and Chronic Migraine Prevention: Trending the First Year of US Adoption
Authors: Virginia R. Schobel, MSc; Jennifer Robinson MSc BACKGROUND: Compare early launch perceptions and self-reported prescribing patterns for the anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) class, specifically erenumab-aooe (available since May 2018), fremanezumab-vfrm (September 2018), galcanezumab-gnlm, (October 2018), for the preventive treatment of episodic and chronic migraine. Assess how anti-CGRP mAb class uptake impacts […]
Eli Lilly’s Emgality is Perceived as Increasingly Competitive with Amgen/Novartis’ Aimovig and Teva’s Ajovy in the US Migraine Prevention Market, as the Anti-CGRP Brand Pulls Ahead on Payer Approval Ease and Overall Prescriber Satisfaction
Assuming positive regulatory outcomes for the preventive treatment of migraine, Biohaven Pharmaceuticals’ rimegepant and Allergan’s atogepant will quickly erode injectable anti-CGRP therapy share, resulting in a dominant position within the class, according to the 4th wave of Spherix Global Insights’ report series Download Report Overview EXTON, Pa., July 2, 2019 ― US neurologists and migraine […]
Biogen Drops After Piper Jaffray Downgrade, Price Target Cut
From: TheStreet By: Tony Owusu Biogen shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company’s multiple sclerosis treatments. The firm also lowered its price target to $250 from […]
Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition
From: Barron’s By: Josh Nathan-Kazis Biogen stock was slipping on Friday morning as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors. Citing data from a proprietary survey of doctors treating MS patients, PiperJaffray analyst Christopher Raymond outlined threats to […]
With Novartis’ Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono’s Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
Bolstering Tecfidera’s competitiveness with the glatiramer acetate class among treatment-naïve relapsing-remitting multiple sclerosis patients is Biogen’s best defense against anticipated near-term share constriction, according to the 14th wave of the quarterly Spherix Global Insights report Download Report Overview EXTON, Pa., June 26, 2019 ― During the last week of March 2019, both Novartis’ Mayzent and […]
